
Tarsier Pharma Ltd.
TARXDormantTarsier Pharma Ltd. · NYSE · Research source · F-1/A · 2026-07-16
IPO research
Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.
Full source-backed summary
Tarsier Pharma is proposing an NYSE IPO of 5,555,555 ordinary shares at an estimated $8.00–$10.00 per share. The company is a loss-making, late-clinical-stage biopharmaceutical issuer whose lead candidate has not met its primary Phase 3 endpoint; substantial clinical, regulatory, financing and dilution risks remain.
Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.
- Business and development direction
Tarsier Pharma Ltd.
Current business Future development
Key risks
Risk 1
The company expects continued substantial losses and estimates $65–$85 million may be required to execute its TRS01 commercialization plan.
Risk 2
No assurance is given that the NYSE listing will be approved or that an active trading market will develop.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Offering quality | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
| # | Institution | Underwriting allocation | Ratio | Shares |
|---|---|---|---|---|
| 1 | Konik Capital Partners, LLC, a division of T.R. Winston |
IPO CAPITAL QUALITY
Basis and evidence
F-1/A · 2026-07-16
Tarsier Pharma’s preliminary IPO contemplates 5,555,555 ordinary shares at $8.00–$10.00 per share and a proposed NYSE listing under TARX.
Offering structure
| Measure | Reported value | Unit |
|---|---|---|
| Shares offered | 5,555,555 | Shares |
Source and calculation
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
SEC table 6 row 1; source 273677:293997; SHA256 2f9e8baa7413d271156aa359dff99e76f15d6ef7f00bfbf9b699cc5c2abaee7b ↗Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Use of proceeds | Source-linked structured inputs are not yet available. Open filing ↗ |
Dilution and valuation
Reported figures remain on their stated basis. Exact compatible price and whole-issuer post-offer inputs are required for calculations.
| Calculation | Shares | Value | Reference |
|---|---|---|---|
| Post-offer shares — base/no option | 29,291,825 | — | |
| Post-offer shares — full option | 30,125,158 | — | |
| Shares offered | 5,555,555 | — |
Basis and evidence ↗
Prospectus share summary; Ordinary shares to be outstanding after this offering; 29,291,825 shares (or 30,125,158 shares if the underwriter exercises its over-allotment option in full).; selected security: shares; selected scenario: base/no option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Exact input · Post-offer shares — base/no option: 29,291,825
Prospectus share summary; Ordinary shares to be outstanding after this offering; 29,291,825 shares (or 30,125,158 shares if the underwriter exercises its over-allotment option in full).; selected security: shares; selected scenario: full option; no inferred sum, conversion or equity value
Figures retain their stated source scenario and conditions.
Prospectus offering table; stated base scenario and source conditions
Prospectus offering table; stated base scenario and source conditions Figures retain their stated source scenario and conditions.
Share-count comparison
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Source ↗IPO valuation scenario simulator
Source inputs required
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
Source ↗Source and calculation ↗
Compatible source-bound inputs are not available; absence is not a non-disclosure finding.
Reported whole-issuer base counts retain explicit option, conversion and surrender assumptions.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
A compatible whole-issuer pre-offer share count is missing; existing-holder or offered-share allocations cannot substitute for it.
Each reported full-option, actual, diluted or class-specific case remains independent; no class sum or cross-date substitution is inferred.
Source facts remain available under their explicit security, scenario, period and precision; required compatible inputs are incomplete.
The current source URL, accession, hash, proof variants, footnotes, input IDs and executable formulas remain attached. Missing source dates and precision gaps remain explicit.
Sources and calculation notes
Read this report’s SEC filing ↗
| View | Source basis |
|---|---|
| Ownership across stages | Some sourced inputs are available; a compatible set is needed for this view. Open filing ↗ |
- As of
- 2026-07-16
Relationship filters
Select for details · Tarsier Pharma Ltd.
Holdings and voting rights
Holder groups may overlap; these rows are not an additive ownership partition.
| Holder / measure | Shares | Ownership | Voting rights | Reference |
|---|---|---|---|---|
| Daphne Haim-Langford, Ph.D.Beneficial shares | 7,068,350 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Zohar Milman, M.Sc.Beneficial shares | 570,630 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Ron Neumann, M.D.Beneficial shares | 287,720 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Susan Benton, MBABeneficial shares | 127,020 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Sascha Bucher, MBABeneficial shares | 127,020 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| All directors and executive officers as a group (8 persons)Beneficial shares | 8,751,370 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| AJ Tarsier Investment LLCBeneficial shares | 1,929,000 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Oriella Ltd.Beneficial shares | 2,563,700 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Alkaloida Chemical Company zrt.Beneficial shares | 4,762,840 | — | — | Ordinary Shares Beneficially Owned; source column 3; stage header not connected |
| Daphne Haim-Langford, Ph.D.Beneficial ownership | — | 29.8%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| Daphne Haim-Langford, Ph.D.Beneficial ownership | — | 23.5%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| Zohar Milman, M.Sc.Beneficial ownership | — | 2.4%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| Zohar Milman, M.Sc.Beneficial ownership | — | 1.9%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| Ron Neumann, M.D.Beneficial ownership | — | 1.2%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| Ron Neumann, M.D.Beneficial ownership | — | 0.9%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| All directors and executive officers as a group (8 persons)Beneficial ownership | — | 33.4%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| All directors and executive officers as a group (8 persons)Beneficial ownership | — | 26.3%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| AJ Tarsier Investment LLCBeneficial ownership | — | 8.13%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| AJ Tarsier Investment LLCBeneficial ownership | — | 6.4%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| Oriella Ltd.Beneficial ownership | — | 10.8%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| Oriella Ltd.Beneficial ownership | — | 8.5%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| Alkaloida Chemical Company zrt.Beneficial ownership | — | 20.06%Beneficial | — | Percent of Ordinary Shares Beneficially Owned Before Offering |
| Alkaloida Chemical Company zrt.Beneficial ownership | — | 15.8%Beneficial | — | Percent of Ordinary Shares Beneficially Owned After Offering |
| Ordinary Shareper-share voting rights | — | — | 1 vote per shareVotes per share | Literal source per-share voting entitlement; Ordinary Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained |
Source and calculation ↗
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Daphne Haim-Langford, Ph.D.
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Zohar Milman, M.Sc.(1)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Ron Neumann, M.D.(1)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Susan Benton, MBA(1)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Sascha Bucher, MBA
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: All directors and executive officers as a group (8 persons)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: AJ Tarsier Investment LLC(2)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Oriella Ltd.(3)
Exact source ownership column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; holders may overlap; not an additive partition
Raw source column: Ordinary Shares Beneficially Owned; source column 3; stage header not connected; source holder: Alkaloida Chemical Company zrt.(4)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Daphne Haim-Langford, Ph.D.
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Daphne Haim-Langford, Ph.D.
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Zohar Milman, M.Sc.(1)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Zohar Milman, M.Sc.(1)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Ron Neumann, M.D.(1)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Ron Neumann, M.D.(1)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: All directors and executive officers as a group (8 persons)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: All directors and executive officers as a group (8 persons)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: AJ Tarsier Investment LLC(2)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: AJ Tarsier Investment LLC(2)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Oriella Ltd.(3)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Oriella Ltd.(3)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned Before Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned Before Offering; source holder: Alkaloida Chemical Company zrt.(4)
Exact source ownership column: Percent of Ordinary Shares Beneficially Owned After Offering; holders may overlap; not an additive partition
Raw source column: Percent of Ordinary Shares Beneficially Owned After Offering; source holder: Alkaloida Chemical Company zrt.(4)
Literal source per-share voting entitlement; Ordinary Share; full source conditions retained; not a holder voting percentage, ownership amount or controller finding; Source capital-stock section conditions: source capital/articles apply at the stated offering completion or closing stage; complete original context retained
• equal right to attend and to vote at all of our general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which attend the meeting and participate at the voting, either in person or by a proxy or by a written ballot, to one vote; Source context: Upon the closing of this offering, our authorized share capital will consist of 100,000,000 ordinary shares, par value NIS 0.001 per share, of which, effective immediately prior to the closing of this offering, 29,291,825 shares will be issued and outstanding (assuming that the underwriter does not exercise its option to purchase additional ordinary shares).
Economic ownership
A chart needs complete, non-overlapping economic interests on one date and share basis. The disclosed holder figures remain in the table.
Share supply
Source lock-up conditions
Literal day restriction; after closing of this offering; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,After closing of this offering · Source conditions apply | 180 days |
Source and calculation
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.
SEC lock-up paragraph; source 2154099:2155385; SHA256 34dd61b389efcc807687dff4916c6cc9c5a8946fdb42119a8c657db1bff5d244 ↗Source lock-up conditions
Literal day restriction; anchor not separately resolved; full conditions and exceptions remain in the source paragraph
| Measure | Reported value |
|---|---|
| the warrants | 180 days |
Source and calculation
issued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part.
SEC lock-up paragraph; source 2164779:2166846; SHA256 74e0317177509bf0cabfad278f7eab276d06b958fdebf6c612bc283ea4f13646 ↗Conditional lock-up timeline
Conditional lock-up timeline
Eligibility is not a sale. Release conditions, holder groups and exceptions remain separate.
closing of this offering
- We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering,We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.
| Holder / event | Term / date | Conditions |
|---|---|---|
| We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, | 180 days | We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements. |
Milestones and unconfirmed releases
| Holder / event | Term / date | Conditions |
|---|---|---|
| the warrants | 180 days | issued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part. |
Basis and evidence
We and our officers and directors, and the holders of 5.0% or more of the outstanding ordinary shares prior to this offering, have agreed, subject to limited exceptions, for a period of 180 days after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any ordinary shares or ordinary shares or any securities convertible into or exchangeable for our ordinary shares or the ordinary shares either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the underwriter. The underwriter may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.
SEC lock-up paragraph; source 2154099:2155385; SHA256 34dd61b389efcc807687dff4916c6cc9c5a8946fdb42119a8c657db1bff5d244 ↗issued in this offering. The warrants are deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The underwriter (or its permitted assignees under Rule 5110(e)(2) of FINRA) will not sell, transfer, assign, pledge, or hypothecate these warrants or the securities underlying these warrants, nor will it engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the warrants or the underlying securities for a 180 day period from the commencement of sales of the ordinary shares in this offering. The warrants will expire five years from the commencement of sales of ordinary shares in this offering. The exercise price and number of ordinary shares issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. We have agreed to a one time demand registration of the ordinary shares underlying the warrants for a period of five years from the commencement of sales of this offering. The warrants also provide for unlimited “piggyback” registration rights at our expense with respect to the underlying ordinary shares during the five year period from the commencement of sales of this offering. The underwriter’s warrants and the ordinary shares underlying the underwriter’s warrants are being registered on the registration statement of which this prospectus forms a part.
SEC lock-up paragraph; source 2164779:2166846; SHA256 74e0317177509bf0cabfad278f7eab276d06b958fdebf6c612bc283ea4f13646 ↗Financial quality
Bars compare absolute amounts within each measure. Each measure has its own scale.
Net income / (loss)
USD · Annual values as reportedOperating cash flow
USD · Annual values as reported| Calculation | FY2024 | FY2025 |
|---|---|---|
| Net income / (loss) | USD 2,456,000 | USD 5,070,000 |
| Operating cash flow | (USD 1,913,000) | (USD 1,318,000) |
| Calculation | Reported value | Reference |
|---|---|---|
| Cash and cash equivalents2025-12-31 | USD 1,999,000 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Cash and cash equivalents2024-12-31 | USD 1,218,000 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Current assets2025-12-31 | USD 2,015,000 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Current assets2024-12-31 | USD 1,266,000 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Total assets2025-12-31 | USD 2,325,000 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Total assets2024-12-31 | USD 1,287,000 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Current liabilities2025-12-31 | USD 812,000 | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Current liabilities2024-12-31 | USD 561,000 | December 31, 2024; issuer; USD; as of 2024-12-31 |
| Total equity / (deficit)2025-12-31 | (USD 4,991,000) | December 31, 2025; issuer; USD; as of 2025-12-31 |
| Total equity / (deficit)2024-12-31 | (USD 2,765,000) | December 31, 2024; issuer; USD; as of 2024-12-31 |
| General and administrative expensesFY2025 | USD 544,000 | FY2025; issuer; USD; year ended 2025-12-31 |
| General and administrative expensesFY2024 | USD 364,000 | FY2024; issuer; USD; year ended 2024-12-31 |
Basis and evidence
Financial quality and runway
Financial quality and runway
Audited U.S. GAAP financial statements cover 2024 and 2025. The company reported 2025 net loss of $5.070 million, accumulated deficit of $26.929 million and cash of $1.999 million as of December 31, 2025. The auditor highlighted substantial doubt about going concern.
EvidenceFinancial review 1Net loss increased from $2.456 million in 2024 to $5.070 million in 2025.
+
Net loss increased from $2.456 million in 2024 to $5.070 million in 2025.
EvidenceFinancial review 2The auditor stated that losses, negative operating cash flows and accumulated deficit raise substantial doubt about going concern.
+
The auditor stated that losses, negative operating cash flows and accumulated deficit raise substantial doubt about going concern.
Baseline filing — comparison pending
No source-comparable material changes identified in this report.
No source-comparable material changes identified in this report.
F-1/A0001213900-26-078792 ↗
Loading filing history…
The company expects continued substantial losses and estimates $65–$85 million may be required to execute its TRS01 commercialization plan.
- Evidence
- RISK FACTORS ↗
No assurance is given that the NYSE listing will be approved or that an active trading market will develop.
- Evidence
- THE OFFERING ↗